Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma Treatments

EGFR mutation-induced drug resistance has become a major threat to the treatment of non-small-cell lung carcinoma. Essentially, the resistance mechanism involves modifications of the intracellular signaling pathways. In our work, we separately investigated the EGFR and ErbB-3 heterodimerization, reg...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Debby D., Ma, Lichun, Wong, Maria P., Lee, Victor H. F., Yan, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4439022/
https://www.ncbi.nlm.nih.gov/pubmed/25993617
http://dx.doi.org/10.1371/journal.pone.0128360

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4439022/
https://www.ncbi.nlm.nih.gov/pubmed/25993617
http://dx.doi.org/10.1371/journal.pone.0128360

Ejemplares similares